GILD ▲ +0.4% - Gilead Sciences, Inc. $GILD Phase 2 SWIFT Study of Emvistegrast, a Potential Differentiated Once-daily Oral Treatment, Meets Primary Endpoint in Ulcerative Colitis. 19-OCT-2026 06:20 AM ET